BioinvestGPT

BioinvestGPT ApS · Research use only

NCT04104672 (AB680 Zimberelimab Nab-paclitaxel Gemcitabine in Advanced Pancreatic Cancer): BVCT ex-ante prediction vs. reported outcome

On 18 Jun 2023, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 16 Jan 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT04104672
Acronym
ARC-8
Drug Name
AB680 Zimberelimab Nab-paclitaxel Gemcitabine
Drug MoA
CD73 inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Advanced Pancreatic Cancer
Human Patients
195
Sponsor
Arcus Biosciences
Phase
Phase 1

Prediction of , index 508

Prospective Prediction
Prediction Index
508
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit)
Technical Prediction
FAILURE (statistically insignificant additive clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
212 days in advance
Readout Data Interpretation
ORR/OS/PFS endpoints not met for both Q+ SoC and QZ+ SoC with mOS trend (15 vs 12 months for SoC).
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies
Phase
Phase 1
Status
Completed
Enrollment
196
Lead sponsor
Arcus Biosciences, Inc.
Conditions
Advanced Pancreatic Cancer
Interventions
DRUG: AB680; DRUG: Zimberelimab; DRUG: Nab-paclitaxel; DRUG: Gemcitabine
Design
Randomized · Sequential · None
Primary purpose
Treatment
Start
2019-11-06
Primary completion
2026-07-21
Completion
2026-07-21
Primary outcomes
  • Number of participants with Treatment Emergent Adverse Events (TEAEs) (From first dose date to 90 days after the last dose (approximately 1 year))
  • Number of Participants With Dose Limiting Toxicities (From First dose to day 28)

NCT04104672 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials